Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer

被引：1

作者：

Hotta, Katsuyuki ^{[1
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Kita Ku, Okayama 7008558, Japan

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2011年 / 11卷 / 07期

关键词：

elrotinib; non-small-cell lung cancer; toxicity; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; PREVIOUSLY TREATED PATIENTS; JAPANESE PATIENTS; CLINICAL-SIGNIFICANCE; PRACTICAL MANAGEMENT; EGFR MUTATIONS; GENE-MUTATIONS; SKIN RASH;

D O I：

10.1586/ERA.11.74

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell lung cancer and is now approved in many countries. To date, there have been a number of clinical studies of erlotinib therapy demonstrating its safety as well as its efficacy. This article summarizes clinical study results in advanced non-small-cell lung cancer, so that we can comprehensively understand the toxicities expected with erlotinib in non-small-cell lung cancer patients.

引用

页码：991 / 997

页数：7

共 50 条

[1] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
Lee, Jin Hwa
Lee, Kyoung Eun
Ryu, Yon Ju
Chun, Eun Mi
Chang, Jung Hyun
[J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
[2] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Passaro, Antonio
Alesini, Daniele
Pochesci, Alessia
Cortesi, Enrico
[J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
[3] Erlotinib in patients with advanced non-small-cell lung cancer: a meta-analysis
Gao, Hui
Ding, Xin
Wei, Dong
Cheng, Peng
Su, Xiaomei
Liu, Huanyi
Aziz, Fahad
Wang, Daoyuan
Zhang, Tao
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (02) : 129 - 144
[4] Erlotinib in non-small-cell lung cancer
Gridelli, Cesare
Rossi, Antonio
Malone, Paolo
Colantuoni, Giuseppe
Del Gaizo, Filomena
Ferrara, Carmine
Nicolella, Dario
Guerriero, Ciro
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592
[5] Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer
Perez Carrion, Ramon
Cubillo Gracian, Antonio
Salinas Hernandez, Pedro
[J]. CLINICAL LUNG CANCER, 2007, 8 (07) : 425 - 428
[6] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
Francesco Grossi
Erika Rijavec
Maria Giovanna Dal Bello
Carlotta Defferrari
Annalisa Brianti
Giulia Barletta
Carlo Genova
Carmelina Murolo
Maurizio Cosso
Gabriella Fontanini
Laura Boldrini
Mauro Truini
Paolo Pronzato
[J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1407 - 1412
[7] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
Grossi, Francesco
Rijavec, Erika
Dal Bello, Maria Giovanna
Defferrari, Carlotta
Brianti, Annalisa
Barletta, Giulia
Genova, Carlo
Murolo, Carmelina
Cosso, Maurizio
Fontanini, Gabriella
Boldrini, Laura
Truini, Mauro
Pronzato, Paolo
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1407 - 1412
[8] Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
Rudin, C. M.
Cervantes, A.
Dowlati, A.
Besse, B.
Ma, B.
Costa, D. B.
Schmid, P.
Heist, R.
Villaflor, V. M.
Spahn, J.
Li, S.
Cha, E.
Riely, G. J.
Gettinger, S.
[J]. ESMO OPEN, 2023, 8 (02)
[9] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
Zheng-Tao Zhou
Xin-Hua Xu
Qing Wei
Ming-qian Lu
Jie Wang
Cai-Hong Wen
[J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127
[10] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
Zhou, Zheng-Tao
Xu, Xin-Hua
Wei, Qing
Lu, Ming-qian
Wang, Jie
Wen, Cai-Hong
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1123 - 1127

← 1 2 3 4 5 →